Printer Friendly

ALAMAR BIOSCIENCES ADDS MAJOR ANTIBIOTIC TO DIAGNOSTIC TEST KITS AFTER SECURING FDA CLEARANCE

 SACRAMENTO, Calif., April 22 /PRNewswire/ -- Alamar Biosciences Inc. (NASDAQ: ALMR), a research and development company that develops, manufactures and markets in vitro testing products, today announced it has received clearance from the U.S. Food and Drug Administration (FDA) to add an important antibiotic to its test kits. Amoxicillin/clavulanate, a widely used drug for treating respiratory, urinary and skin infections, is now available for use in the company's test kits that determine which antibiotic and what dosage will be effective in treating gram-positive bacterial infections.
 With the addition of amoxicillin/clavulanate, which is manufactured by Smith Kline Beecham Laboratories, Alamar now has 20-gram positive and 31-gram negative antibiotics cleared by the FDA, all of which are available for inclusion in its user-defined diagnostic kits.
 Currently, Alamar has six applications pending before the FDA, four of which are related to the company's bacterial identification test kit and a semi-automated test-reading instrument. Once cleared, these two products will complete Alamar's initial product portfolio for manual and semi-automated bacterial identification and antibiotic susceptibility testing. This product portfolio will be capable of collectively addressing approximately two-thirds of an estimated $530-million market. The FDA has had the 510(k) applications for the identification kit and reading instrument for over 90 days, and the company has responded to all FDA inquiries and questions to date. Alamar has no reason to believe that clearance will not be forthcoming in the near future.
 Common stock in Alamar Biosciences Inc. is traded on NASDAQ under the symbol ALMR. The company develops, manufactures and markets in vitro (outside the body) testing products for hospitals, reference laboratories and other healthcare providers. Alamar also markets alamarBlue(TM), an indicator dye for determining cell viability in research and biotechnology applications.
 NOTE: For information on Alamar Biosciences Inc. by fax, dial 800-PRO-INFO, extension 141.
 -0- 4/22/93
 /CONTACT: Kenneth Miller, chief executive officer of Alamar, 916-567-3475; or Elizabeth Truax, 415-986-1591, or Kathy Brunson, 312-266-7800, both of The Financial Relations Board, for Alamar/
 (ALMR)


CO: Alamar Biosciences Inc.; Smith Kline Beecham Laboratories ST: California IN: MTC SU: PDT

ML-GT -- SF002 -- 9207 04/22/93 09:04 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 22, 1993
Words:354
Previous Article:SEC CLEARS FLUKE PROXY MATERIALS RELATING TO THE ACQUISITION OF PHILIPS TEST & MEASUREMENT BUSINESS
Next Article:VERIFONE INCREASES STAKE IN SYSTEM FINANCING COMPANY TO 48.9 PERCENT; WILL GENERATE RECURRING REVENUE FROM LEASING PORTFOLIO
Topics:


Related Articles
ALAMAR BIOSCIENCES REPORTS SECOND QUARTER RESULTS
ALAMAR BIOSCIENCES ADDS 3NET SOFTWARE TO GROWING PRODUCT LINE
ALAMAR BIOSCIENCES ADDS MAJOR ANTIBIOTIC TO DIAGNOSTIC TEST KITS AFTER SECURING FDA CLEARANCE
ALAMAR BIOSCIENCES REPORTS THIRD QUARTER, NINE MONTHS RESULTS
ALAMAR BIOSCIENCES SECURES FDA CLEARANCE FOR READING INSTRUMENT; MOVES CLOSER TO COMPLETING PRODUCT LINE
ALAMAR BIOSCIENCES LAUNCHES PRODUCT LINE AFTER FDA CLEARANCE OF GRAM NEGATIVE BACTERIA ID TEST
ALAMAR BIOSCIENCES RECEIVES LAST PENDING FDA CLEARANCE; FULL PRODUCT LINE NOW AVAILABLE WORLDWIDE
ALAMAR BIOSCIENCES UNVEILS NEW PRODUCT; AUTOMATED INOCULATION DEVICE TO SERVICE LARGE CUSTOMERS
ALAMAR ANNOUNCES THIRD QUARTER EARNINGS
ACCUMED INTERNATIONAL, INC. AND BIOKIT S.A. ENTER INTO JOINT VENTURE

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters